- Overview:
- This clinical trial will study how safe and effective a new drug is for children and adolescents with certain growth conditions.
- Staus:
- Enrolling
- Clinical Description:
- This clinical trial will study how safe and effective a new drug called lonapegsomatropin* is for children and adolescents with certain growth conditions. These include TS, SHOX-D, SGA, or ISS. The new drug is a once-a-week injection and will be compared to somatropin, a once-a-day injection that is already approved for some uses. *Lonapegsomatropin is still being studied and has not yet been approved for use in children and adolescents with Turner Syndrome, SHOX Deficiency, Small for Gestational Age, and Idiopathic Short Stature
- Target Age/Sex:
- Male & Female Children Ages 2 and Under 18
- Benefits:
- Participants will receive at no cost: study product, study materials, study-specific lab tests and procedures. You may also be reimbursed for travel costs.
- Study Length:
- About 56 weeks
- Link:
- ClinicalTrials.gov
